Tackling Traumatic Brain Injury (TBI) in Montana Patel’s

Document Type


Publication Date



Patel’s group studies changes in RNA molecules in dis-ease, such as TBI, ALS, and brain tumors. Recent work has identified microRNAs that may serve as potential blood-based biomarkers for developing novel diagnostic tests and therapeutics for neurological disorders. In 2016, he co-founded a Missoula-based company, FYR Diag-nostics, LLC to develop miRNA biomarker technologies.

Streaming Media


Sarjubhai A. Patel is Associate Research Professor of Molecular Pharmacology at the Skaggs School of Pharmacy at UM-Missoula. After completing an under-graduate degree in Pharmacology at the University of Sunderland, UK, Patel earned a M.Sc. in Neuroscience from King’s College London followed by a Ph.D. in Phar-maceutical Sciences from UM. Patel returned to UM as a Research Associate in the NIH-COBRE Center for Structural and Functional Neuroscience following a post-doc at John Hopkins Hospital. He has received two GE-NFL Head Health Challenge awards and a Montana Re-search & Economic Development Initiative (MREDI) grant to work on TBI.